VantAI

Founded in 2019, VantAI integrates GenAI with drug discovery to develop computational models that reveal hidden connections between molecules, targets, and diseases, making protein interactions programmable. The company uses geometric deep learning platforms to focus on induced proximity modulators, which are designed to unlock the full potential of proximity modulator modalities for drug discovery. 

The company also designs protein degraders by leveraging deep learning to understand and model complex biological interactions, particularly protein-protein interactions. VantAI's Protein-Contact-First method uses geometric deep learning to mimic naturally evolved interfaces, aiding in creating effective and precise drug candidates.

The company is a subsidiary of Roivant Sciences.

Key customers and partnerships

VantAI has established partnerships within the biopharmaceutical industry to enhance drug discovery and development. Notably, in February 2024, the company entered a collaboration worth USD 674 million with Bristol Myers Squibb to accelerate the discovery of novel drug candidates, including molecular glues and protein degraders. The company also partnered with Blueprint Medicines in January 2024 to create innovative protein degradation therapies that tackle challenging disease targets. In April 2022, VantAI partnered with Janssen Pharmaceutical t o develop novel molecular glue and protein degrader drug candidates for certain diseases using VantAI's geometric deep-learning platform.